Gilead Sciences Inc. said on Monday it would buy Forty Seven Inc for US$4.9-billion in cash, adding an experimental treatment that targets blood cancer to its portfolio of oncology drugs.
Shares of Forty Seven jumped 62 per cent, trading slightly below the offer price of US$95.50 a share. Gilead shares were up 2.3 per cent at US$70.95 in early morning trading.
The deal is expected to complement the portfolio of Kite Pharma Inc., which the company acquired for US$12-billion in 2017, and comes at a time when sales of Gilead’s hepatitis C drugs have seen a steep fall.
“The deal is in line with the strategy CEO Daniel O’Day had laid out earlier in the year, but I think he and his management need to do something more impactful,” Credit Suisse analyst Evan Seigerman said.
Through the acquisition, Gilead will have access to Forty Seven’s lead drug, magrolimab, which switches off a “do not eat me” signal known as CD47 expressed by tumour cells that lets them avoid destruction. The drug is in early-stage testing.
CD47 antibodies are a relatively new class of drugs in development for treating cancer, a lucrative but difficult market to enter for drug makers.
Initially focused on treating blood cancers called myelodysplastic syndromes, magrolimab could be used alongside Yescarta, a CAR-T therapy Gilead gained through the Kite acquisition, in the future, Gilead executives said.
“There are studies ongoing and data being generated in DLBCL, and that’s one of those areas where I think you could imagine that there could be … possibilities,” Gilead chief medical officer Merdad Parsey said.
Diffuse large B-cell lymphoma, or DLBCL, is a type of non-Hodgkin’s lymphoma that is currently being treated with Yescarta and for which magrolimab is being tested as a treatment.
Gilead’s Yescarta, a CAR-T therapy added through the acquisition of Kite, has gained market share as a treatment for certain types of DLBCL, SunTrust analysts said on Thursday, citing a Bloomberg News report that Gilead had approached Forty Seven with a takeover offer.
However, the market could in the future be split between treatments such as Forty Seven’s magrolimab and CAR-T therapies, according to SunTrust analysts Robyn Karnauskas and Asthika Goonewardene.